Drug Profile
Fexinidazole - Drugs for Neglected Diseases initiative/Sanofi
Alternative Names: Fexinidazole Winthrop; Fexinidazole Winthrop H-W-2320; HOE-239Latest Information Update: 06 Feb 2024
Price :
$50
*
At a glance
- Originator Hoechst Pharma
- Developer Drugs for Neglected Diseases Initiative Foundation; Sanofi
- Class Antiprotozoals; Ethers; Nitroimidazoles; Organic sulfur compounds; Skin disorder therapies
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered African trypanosomiasis
- Phase II Chagas disease
- Discontinued Visceral leishmaniasis
Most Recent Events
- 10 Jan 2024 Discontinued - Phase-II for Chagas disease in Spain (PO)
- 10 Jan 2024 Efficacy and adverse events data from a phase II trial in Chagas disease released by Drugs for Neglected Diseases initiative
- 15 Dec 2023 Committee for Medicinal Products for Human Use (CHMP) recommends approval of fexinidazole for African trypanosomiasis